2 results
Not approvedWill not start
Primary:* To prove the superiority of a 48-weeks treatment with 3.2 g/day delayedreleasephosphatidylcholine (LT-02) versus placebo for the maintenance ofremission in patients with ulcerative colitis (UC)Secondary:* To study safety and tolerability…
Approved WMORecruiting
Primary Objective:Part 1 Dose Escalation• To investigate the safety and tolerability of LAVA-051 in patients with relapsed/refractory CLL, MM, or AML. • To determine the RP2D of LAVA-051 in patients with relapsed/refractory CLL, MM or AML.Part 2…